)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Medclair
Medclair (MCLR) investor relations material
Medclair Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Order intake for Q2 2026 reached 25.1 MSEK, nearly doubling compared to Q2 2025, supporting future growth.
Net sales for Q2 2026 were 14.3 MSEK, with H1 2026 net sales totaling 32.5 MSEK.
Book-to-bill ratio for Q2 2026 stood at 1.76, indicating robust demand.
EBITDA for H1 2026 was SEK 6.3 million, down from SEK 10.0 million in H1 2025, reflecting increased investments in international expansion.
International expansion included new markets in Singapore and New Zealand, positioning for continued growth.
Financial highlights
H1 2026 order intake was SEK 41.2 million, up from SEK 34.7 million in H1 2025.
H1 2026 net sales reached SEK 32.5 million, a slight increase from SEK 31.4 million in H1 2025.
Book-to-bill ratio for Q2 2026 was 1.76, up from 0.80 in Q2 2025.
Cash and cash equivalents at period end were SEK 18.9 million, up from SEK 1.3 million in June 2025.
Profit after tax for H1 2026 was SEK 3.3 million, with a Q2 2026 loss after tax of SEK -0.4 million.
Outlook and guidance
Full-year sales are expected to exceed 2025 levels, supported by a strong order book and positive Q3 start.
Continued global expansion strategy with operations in over 20 countries.
Diversification across healthcare, dental, and industrial segments supports multiple growth paths.
Favorable long-term market conditions driven by regulatory and sustainability trends.
Continued investments in commercial scale-up, patent protection, and new product platforms.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Medclair
- Sales growth, strong margins, and new tech drive expansion in a SEK 17 billion market.MCLR
Q1 2026 - Record sales and profit growth in 2025, with global expansion and strong dental segment momentum.MCLRQ4 2025
- Strong Q3 growth, profitability, and global expansion drive leadership in sustainable gas solutions.MCLRQ3 2025
- Q2 2025 saw 24% revenue growth, strong margins, and major international orders.MCLRQ2 2025
- Order intake and global expansion offset Q3 sales dip; climate-driven demand remains robust.MCLRQ3 2024
- Net sales up 43% and net income positive, with strong market expansion and Spintso divestment.MCLRQ2 2024
- Order growth and international expansion drive Medclair's positive earnings turnaround.MCLRQ4 2024
- 35% revenue growth and strong margins position Medclair for further expansion.MCLRQ1 2025
Next Medclair earnings date
Q3 20265 Nov, 2026
Medclair
Next Medclair earnings date
Q3 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Medclair AB is a Swedish company specializing in environmental solutions for healthcare, particularly focused on reducing nitrous oxide emissions in medical settings. The company develops and manufactures equipment that captures and neutralizes nitrous oxide used during medical procedures, minimizing environmental impact and improving air quality in healthcare facilities. Medclair’s products are widely used in hospitals and clinics, particularly in obstetrics and dentistry, to enhance safety for healthcare providers and patients. The company is headquartered in Stockholm, Sweden, and its shares are listed on the Spotlight Stock Market.